Menu

I

IgGenix

Verified

Visit Website Connect with Founders

Develop first-in-class therapies for millions of people whose daily lives are limited by allergies Biotech

About IgGenix

IgGenix builds in the startup category and is tracked by 100Xfounder for operating momentum, talent growth, and market execution.

What they do: Develop first-in-class therapies for millions of people whose daily lives are limited by allergies Biotech

Funding context: Khosla Ventures, $40M Series B in 2023

Recent milestones:

IgGenix appears in the 100Xfounder startup directory import feed.

Why it Matters

IgGenix matters because develop first-in-class therapies for millions of people whose daily lives are limited by allergies Biotech

Funding Snapshot

Total Funding: $40.00MLast Round: Series B Khosla Ventures, $40M Series B in 2023All Rounds: 1

Series B | Khosla Ventures, $40M Series B in 2023

Hiring Roles

This company is actively hiring.

Open Roles

Meet the Founders

IgGenix Team

IgGenix Team

Founder & CEO

Tech Stack

AWSReactPythonPostgreSQL

Last updated: April 17, 2026

IgGenix intelligence brief

This profile combines core company context with linked founder, funding, and newsroom routes so readers can evaluate business momentum without switching across multiple tools. Use it as a baseline for comparing peers in the same industry and stage.

For deeper validation, pair this page with founder profile, company news coverage, and stage-based funding hubs to contextualize updates against wider market movement.

Related Companies

Alternatives in Startup with comparable market signals.

V

Varda Team

View Company Compare Alternatives

F

Flexport Team

View Company Compare Alternatives

D

DevRev Team

View Company Compare Alternatives

I

insitro Team

View Company Compare Alternatives

P

PatSnap Team

View Company Compare Alternatives

S

Solugen Team

View Company Compare Alternatives

G

Gong.io Team

View Company Compare Alternatives

K

Klook Team

View Company Compare Alternatives

Discover Now

Newsroom and topic pages connected to IgGenix.

Company News Hub Topic Hubs Funding News

No company-specific newsroom stories available yet.

Contextual Research Links

Jump to country, industry, stage, startup taxonomy, and newsroom routes tied to this company.

Company profile→Company news hub→Founder profile→United States startup directory→United States startup news→Startups in United States→Startup hub→Startup startup list→Series B startups→Series B startup list→

Want to get featured on 100Xfounder?

Want your company featured with founder details and funding visibility? Start here.

Contact Editorial Get Featured

FAQs About IgGenix

Common questions people ask about this profile.

What is IgGenix?

Develop first-in-class therapies for millions of people whose daily lives are limited by allergies Biotech

Who founded IgGenix?

IgGenix is associated with IgGenix Team on 100Xfounder.

Where is IgGenix located?

IgGenix is listed in San Francisco Bay Area, California, USA.

What stage is IgGenix in?

IgGenix is currently mapped to Series B. Funding context: Khosla Ventures, $40M Series B in 2023

What is the latest funding round of IgGenix?

IgGenix's latest tracked round is Series B Khosla Ventures, $40M Series B in 2023. Total tracked rounds: 1.

Is IgGenix hiring now?

IgGenix hiring status: Open Roles.

What technologies does IgGenix use?

IgGenix is associated with AWS, React, Python, and PostgreSQL.

Is IgGenix verified on 100Xfounder?

Yes. IgGenix is currently marked verified on 100Xfounder as of April 17, 2026.

How can users connect with IgGenix founders?

Users can open founder profiles, use listed company links, and track signal updates directly from the 100Xfounder directory.